Mark L. Baum

This profile gathers the share dealings of Mark L. Baum across 3 companies, led by Harrow, Inc., Eton Pharmaceuticals, Inc. and Ideal Power Inc. We count 31 filings; the first trade dates from 19 December 2016 and the latest from 14 May 2026.

On the market, this insider has only ever bought: 8 purchases, €1.2M in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants and 13 option exercises. Since January 2026: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €93k. On 8 out of 8 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. After 8 purchases with a full 90-day history, the hit rate stands at 88% and the median 90-day move at +15.5%. They describe history only and say nothing certain about the share price ahead.

The latest filing, published on 15 May 2026, reports an open-market purchase of €259k in Harrow, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.